Cabaletta Bio, Inc.

NASDAQ: CABA · Healthcare · Biotechnology

PublicHQ Philadelphia, PA · PhiladelphiaCIK 0001759138Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 37DQ —GM —SS 59

v0.1 · 35/100 weight · pillars only

↑ market scale, balance-sheet leverage · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$167.9M

Employees

156

as of 2026-09-12

Market cap

$445.1M

as of 2026-09-12

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$167.9M-$167.9M2025

Operating income-$172.2M-$172.2M2025

Total assets$165.1M$165.1M2025

Liabilities$53.0M$53.0M2025

Equity$112.1M$112.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Cabaletta Bio, Inc.’s financial profile?

Cabaletta Bio, Inc. earned -$167.9M in FY2025 net income.

Peers · Healthcare

Scribe Therapeutics Inc.——Vogenx Inc.——MapLight Therapeutics, Inc.——BridgeBio Oncology Therapeutics Inc.——Kyverna Therapeutics, Inc.——Rezolute, Inc.——

Neighbors

Philadelphia →

Comcast Corporation$123.7B86A Carpenter Technology Corporation$2.9B——Aramark$18.5B65B Five Below, Inc.$4.8B74B Axalta Coating Systems Ltd.$5.1B76B+Urban Outfitters, Inc.$6.2B73B

Key facts

CEOSteven A. Nichtberger

SectorHealthcare

IndustryBiotechnology

HeadquartersPhiladelphia, PA

ExchangeNASDAQ: CABA

Employees156

IPO date2019-10-25

Latest filings

8-K2026-09-14 8-K2026-08-13 10-Q2026-08-13 8-K2026-06-11 8-K2026-06-03 10-Q2026-05-14 8-K2026-05-14 8-K2026-05-14

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.